This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe
Home   Membership   Events   Resources   Accreditation Feb. 23, 2011
 
 
 

Billing and Coding Update for ACRO Members
ACRO    Share   Share on FacebookTwitterShare on LinkedinE-mail article
Time/date: Noon to 1:30 p.m. CST on March 4
Please join Ron DiGiaimo as he discusses coding issues, solutions and updates for 2011. Ron will cover relevant billing issues by disease site, plus common codes utilized in progressive radiation oncology practices, documentation recommendations, and what you need to know regarding the latest efforts to ensure compliance with CMS regulations. There will be ample time allowed at the end for questions and answers.
Reserve your webinar seat now.




Early balding seen doubling prostate cancer risk
Internal Medicine News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Men with prostate cancer are twice as likely to have had male pattern baldness starting at age 20, according to results of a study that found no increased risk among men who began balding in their 30s or 40s. The findings, published Feb. 16 in Annals of Oncology, suggest that men with early baldness may benefit from routine prostate cancer screening or preventive measures that could include the systematic use of 5-alpha reductase inhibitors, the researchers wrote. For their research, Dr. Michael Yassa, who was a radiation oncology fellow at the European Georges Pompidou Hospital in Paris at the time of the study, and his associates studied 388 men with a diagnosis of prostate cancer, recruited from radiation oncology clinics in three French institutions. More

Breast cancer study questions lymph node removal
The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Many women with early breast cancer do not appear to need removal of their lymph nodes, as is often recommended, according to a federally funded study. The study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association. More

Peer-reviewed articles meant to impact your practice of oncology

Visit The Oncologist’s Community Site to read our virtual collection of Radiation articles and the tribute to Dr. Eli Glatstein.
MORE


Scientists discover cell of origin for childhood muscle cancer
ScienceDaily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start. These findings may lead to non-chemotherapy medicines that can inhibit "molecular targets" such as growth factor receptors, thereby stopping or eradicating the disease. Rhabdomyosarcoma is a condition that when spread throughout the body has a survival rate of only 20 to 40 percent. In adults with soft tissue sarcomas, survival can be even lower. Now for the first time the researchers have shown from where these tumors arise and what drives them to grow and spread. More

Protein may be key to new treatment in a childhood cancer
ScienceDaily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity. "Our study implicates this protein as a promising treatment target for high-risk neuroblastoma," said pediatric oncologist Kristina A. Cole, M.D., Ph.D., of the Cancer Center at The Children's Hospital of Philadelphia. "The fact that drugs acting on this protein are already being studied in clinical trials for adult cancers may hasten the process of testing this treatment strategy in children." More



Native American ancestry linked to greater risk of relapse in young leukemia patients
PR Newswire via Yahoo News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The first genomewide study to demonstrate an inherited genetic basis for racial and ethnic disparities in cancer survival linked Native American ancestry with an increased risk of relapse in young leukemia patients. The work was done by investigators at St. Jude Children's Research Hospital and the Children's Oncology Group. Along with identifying Native American ancestry as a potential new marker of poor treatment outcome, researchers reported evidence the added risk could be eliminated by administering an extra phase of chemotherapy. The study involved 2,534 children and adolescents battling acute lymphoblastic leukemia. The work appeared in the advance online edition of the scientific journal Nature Genetics. More

Birth defect risk slightly higher for children of male cancer survivors
HealthDay News via Bloomberg Businessweek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Men who have had cancer are at a slightly higher risk of bearing children with congenital problems such as a cleft palate compared to their peers with no history of cancer, according to new research. But the overall risk was low, researchers from Sweden report in the online edition of the Journal of the National Cancer Institute. And the findings also are reassuring to male cancer survivors who choose to conceive using assisted reproductive technologies, as they have no additional risk over their peers who conceive naturally. More



Study: Women on bone drugs have less colon cancer
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Women taking certain bone drugs after menopause appear less likely to develop colon cancer, Israeli and U.S. researchers said. The finding has them excited about the prospect of using the drugs — called bisphosphonates — to help prevent cancer in healthy people, but other experts are less enthusiastic. "The lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing," Eric Jacobs of the American Cancer Society, who wasn't involved in the study, told Reuters Health by e-mail. "However, these results should be interpreted with caution and require confirmation by additional studies." More

Dying breast cancer patient calls for personalized medicine
FierceBiotech    Share    Share on FacebookTwitterShare on LinkedinE-mail article
New England-based biotech publicist Adriana Jenkins passed away recently following a 10-year battle with breast cancer. In her 15 years in public relations, she represented many well-known biotechs. Jenkins was diagnosed with an aggressive form of breast cancer when she was just 31. Her doctors discovered that she had HER2-positive breast cancer. And at that time, Genentech was enrolling patients in clinical trials of a groundbreaking new cancer treatment called Herceptin. Herceptin is accompanied by a diagnostic test that determines whether the drug will be effective for the patients based on cancer type. The personalized medicine worked for Jenkins, giving her another nine years of life before the disease spread and finally claimed her life. More

 
 
RadOnc Weekly
Colby Horton, Vice President of Publishing, 469.420.2601   Download media kit
Patrick McCoy, Senior Content Editor, 469.420.2603   Contribute news
This edition of RadOnc Weekly was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Feb. 16, 2011
Feb. 9, 2011
Feb. 2, 2011
Jan. 26, 2011



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063